Literature DB >> 6839242

Diffuse alveolar damage syndrome associated with amiodarone therapy.

F R Jirik, H Henning, V F Huckell, D V Ostrow.   

Abstract

Amiodarone is an effective antiarrhythmic that has been used in Europe for over a decade and has been available for investigational use in North America for a shorter time. It has several well recognized side effects. Recent reports have related pulmonary disorders to the use of this drug; fibrosing alveolitis has been found by lung biopsy. Amiodarone's toxicity to the lung does not appear to be dose-related. Besides cessation of amiodarone administration, management of this complication includes steroid therapy. A case is described of nonspecific diffuse alveolar damage syndrome in a patient who had received amiodarone.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6839242      PMCID: PMC1875323     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN: 0008-4409            Impact factor:   8.262


  13 in total

1.  Amiodarone in the treatment of refractory supraventricular and ventricular arrhythmias.

Authors:  P J Wheeler; R Puritz; D V Ingram; D A Chamberlain
Journal:  Postgrad Med J       Date:  1979-01       Impact factor: 2.401

2.  [Corneal thesaurismosis due to amiodarone. Current data].

Authors:  P Vérin; P Gendre; G Barchewitz; G Laurent-Bronchat; M Yacoubi; S Morax
Journal:  Arch Ophtalmol Rev Gen Ophtalmol       Date:  1971 Aug-Sep

3.  A peculiar cutaneous pigmentation from cordarone.

Authors:  A K Vos; A G van Ramshorst; J C Grosfeld; J P Goossens
Journal:  Dermatologica       Date:  1972

4.  Alveolitis after treatment with amiodarone.

Authors:  S A Riley; S E Williams; N J Cooke
Journal:  Br Med J (Clin Res Ed)       Date:  1982-01-16

5.  Possible association of pneumonitis with amiodarone therapy.

Authors:  H H Rotmensch; M Liron; M Tupilski; S Laniado
Journal:  Am Heart J       Date:  1980-09       Impact factor: 4.749

6.  Pneumonitis and pulmonary fibrosis associated with amiodarone treatment: a possible complication of a new antiarrhythmic drug.

Authors:  S M Sobol; L Rakita
Journal:  Circulation       Date:  1982-04       Impact factor: 29.690

7.  Amiodarone pulmonary toxicity.

Authors:  F E Marchlinski; T S Gansler; H L Waxman; M E Josephson
Journal:  Ann Intern Med       Date:  1982-12       Impact factor: 25.391

8.  Control of refractory cardiac arrhythmias with amiodarone.

Authors:  D Leak; J N Eydt
Journal:  Arch Intern Med       Date:  1979-04

9.  Clinical efficacy and electrophysiology during long-term therapy for recurrent ventricular tachycardia or ventricular fibrillation.

Authors:  J J Heger; E N Prystowsky; W M Jackman; G V Naccarelli; K A Warfel; R L Rinkenberger; D P Zipes
Journal:  N Engl J Med       Date:  1981-09-03       Impact factor: 91.245

10.  Amiodarone therapy in symptomatic, sustained refractory atrial and ventricular tachyarrhythmias.

Authors:  P J Podrid; B Lown
Journal:  Am Heart J       Date:  1981-04       Impact factor: 4.749

View more
  2 in total

1.  Amiodarone pneumonitis: three further cases with a review of published reports.

Authors:  J I Darmanata; N van Zandwijk; D R Düren; E A van Royen; W J Mooi; T A Plomp; H M Jansen; D Durrer
Journal:  Thorax       Date:  1984-01       Impact factor: 9.139

2.  [Amiodarone-induced pneumonitis. Lethal complication in a patient after thoracic surgery].

Authors:  V Ghezel-Ahmadi; V C Kürschner; A Fisseler-Eckhoff; J Schirren; J E Schmitz; T Obenhaus
Journal:  Anaesthesist       Date:  2008-10       Impact factor: 1.041

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.